A detailed history of Two Sigma Investments, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Investments, LP holds 1,674,391 shares of BCRX stock, worth $14.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,674,391
Previous 1,574,641 6.33%
Holding current value
$14.1 Million
Previous $8 Million 29.35%
% of portfolio
0.03%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $411,967 - $677,302
99,750 Added 6.33%
1,674,391 $10.3 Million
Q1 2024

May 15, 2024

SELL
$4.89 - $7.65 $3.8 Million - $5.94 Million
-777,079 Reduced 33.04%
1,574,641 $8 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $2.97 Million - $4.03 Million
595,575 Added 33.91%
2,351,720 $14.1 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $2.85 Million - $3.36 Million
424,657 Added 31.89%
1,756,145 $12.4 Million
Q2 2023

Aug 14, 2023

SELL
$6.96 - $8.81 $61,456 - $77,792
-8,830 Reduced 0.66%
1,331,488 $9.37 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $6.56 Million - $9.78 Million
826,411 Added 160.81%
1,340,318 $11.2 Million
Q4 2022

Feb 14, 2023

SELL
$10.5 - $14.2 $5.43 Million - $7.34 Million
-517,252 Reduced 50.16%
513,907 $5.9 Million
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $8.51 Million - $11.7 Million
788,618 Added 325.15%
1,031,159 $13 Million
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $342,560 - $776,295
43,417 Added 21.8%
242,541 $2.57 Million
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $11.8 Million - $20.2 Million
-1,024,065 Reduced 83.72%
199,124 $3.24 Million
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $11.7 Million - $16.1 Million
-1,044,456 Reduced 46.06%
1,223,189 $16.9 Million
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $5.93 Million - $7.36 Million
417,160 Added 22.54%
2,267,645 $32.6 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $17 Million - $30.9 Million
1,792,116 Added 3070.32%
1,850,485 $29.3 Million
Q1 2021

May 17, 2021

SELL
$7.37 - $13.61 $7.48 Million - $13.8 Million
-1,015,047 Reduced 94.56%
58,369 $594,000
Q4 2020

Feb 16, 2021

SELL
$3.37 - $8.61 $3.01 Million - $7.68 Million
-892,023 Reduced 45.39%
1,073,416 $8 Million
Q3 2020

Nov 16, 2020

SELL
$3.43 - $5.53 $3.08 Million - $4.97 Million
-897,942 Reduced 31.36%
1,965,439 $6.75 Million
Q2 2020

Aug 14, 2020

BUY
$1.9 - $5.61 $3.29 Million - $9.72 Million
1,731,860 Added 153.06%
2,863,381 $13.6 Million
Q1 2020

May 15, 2020

SELL
$1.6 - $4.11 $470,294 - $1.21 Million
-293,934 Reduced 20.62%
1,131,521 $2.26 Million
Q4 2019

Feb 14, 2020

BUY
$1.59 - $3.45 $1.06 Million - $2.3 Million
667,056 Added 87.96%
1,425,455 $4.92 Million
Q3 2019

Nov 14, 2019

BUY
$2.5 - $3.73 $480,575 - $717,017
192,230 Added 33.95%
758,399 $2.17 Million
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $851,352 - $2.68 Million
292,561 Added 106.93%
566,169 $2.15 Million
Q1 2019

May 15, 2019

BUY
$7.38 - $9.72 $1.89 Million - $2.48 Million
255,608 Added 1420.04%
273,608 $2.23 Million
Q4 2018

Feb 14, 2019

SELL
$6.51 - $9.6 $850,524 - $1.25 Million
-130,649 Reduced 87.89%
18,000 $145,000
Q3 2018

Nov 14, 2018

BUY
$5.52 - $7.99 $820,542 - $1.19 Million
148,649 New
148,649 $1.13 Million
Q2 2018

Aug 14, 2018

SELL
$4.6 - $6.52 $244,719 - $346,864
-53,200 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$4.35 - $5.82 $1.04 Million - $1.39 Million
-238,228 Reduced 81.75%
53,200 $254,000
Q4 2017

Feb 14, 2018

BUY
$4.16 - $5.33 $777,424 - $996,075
186,881 Added 178.75%
291,428 $1.43 Million
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $428,642 - $624,145
104,547
104,547 $548,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.57B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.